glp 1 and brain health Role of glucagon-like peptide-1 receptor agonists in Alzheimer's disease Parkinson's disease | Journal of Biomedical Science From metabolism to mind: The

10.1007/s00210-001-0521-y 146 HargreavesM.SprietL

Ultimately, Pfizer discontinued the entire program in April 2025, citing that the risk-benefit profile, including a potential case of drug-induced liver injury (DILI) in a recent study, did not support further development

Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in graves orbitopathy

When selecting a tracking tool, prioritize features like dose reminders , weight and body measurement tracking , food and hydration logs , and symptom monitoring

Type-2 diabetic animal studies have revealed that butyrate has similar effects to metformin in reducing insulin resistance and other T2DM-associated conditions (60)